MPCC

In this fifth episode, Michael A. DiSpezio discusses the quality of life and how it changed following radical prostatectomy. Michael explains the basic difference between external beam radiation and the implantation of radioactive seeds, what radiation does, and addresses [...]

In this fourth episode, Michael A. DiSpezio addresses the first PSA test following surgery and what that means as far as the tumor’s spread. He then presents the basics of cancer in terms of cells and DNA. Then, Michael [...]

In this third episode, Michael A. DiSpezio addresses the concept of quality of life and how one’s choice of treatment impacts the future. He profiles his own challenges with post-operative side effects including urinary incontinence, bowel issues, erectile dysfunction [...]

In this second episode, Michael A. DiSpezio presents the basics of decision making as it pertains to critical choices he faced, including selecting the type of prostate biopsy. He explains what is communicated in a biopsy pathology report. In [...]

In this first episode, Michael A. DiSpezio introduces us to his personal journey with prostate cancer. It begins with addressing PSA and the role of this tumor marker in risk assessment for prostate cancer. He discusses active surveillance as [...]

Mark the 2022 Prostate Cancer Awareness Month with Dr. Michael Lutz, president of the Michigan Institute of Urology’s (MIU) Men’s Health Foundation, and prostate cancer survivor and former Navy pilot, Craig Reiner, as they discuss the current state of [...]

Thanks to MPCC board members Allen Snyder and Analesa Baraka who join MPCC Medical Advisory Committee member Dr. Quoc-Dien Trinh in discussing “Shared Decision Making: Then and Now.” This podcast includes an interview with MPCC chairman Allen Snyder who [...]

 Join Drs. Adam Kibel, Clare Tempany, J. Jacques Carter, Richard Babayan, and Glenn Bubley as they reflect on the advances in prostate cancer diagnosis, treatment and research since the Jack Colbert Memorial Award was established by MPCC in 2008. The [...]

Thanks to David Einstein, MD, from Beth Israel Deaconess Medical Center, for discussing “Into the Unknown: How Do We Study Prostate Cancer Treatments?” For every exciting new therapy, there is a long road of research along which many other [...]

Thanks to Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute for discussing “Exercise as Medicine for Prostate Cancer Survivorship.” Persons at risk and diagnosed with prostate cancer are a vulnerable population in need of non-pharmacologic interventions to improve health outcomes. [...]